Showing results (1331-1340 of 2,692) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|December 17, 2013
Diagnostic point-of-care tests in resource-limited settingsPaul K Drain, Emily P Hyle, Farzad Noubary, et al.
The Lancet. Infectious Diseases|July 16, 2026
Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trialOddvar Oppegaard, Bjørn Blomberg, Rebecca Jane Cox, et al.
The Lancet. Infectious Diseases|July 21, 2026
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort studyInès Fafi, Zaba Valtuille, Florentia Kaguelidou, et al.
The Lancet. Infectious Diseases|July 21, 2026
Genomic epidemiology of invasive meningococcal disease in Scotland before, during, and after the COVID-19 pandemic: a retrospective observational studyNiall Ahmad, Roisin Ure, Laura MacDonald, et al.
The Lancet. Infectious Diseases|July 27, 2026
Empiric tuberculosis treatment in hospitalised adults with advanced HIV disease in Africa: applying the therapeutic threshold to clinical practiceTom Boyles, Jayne Ellis, Nicholas Feasey, et al.
The Lancet. Infectious Diseases|August 4, 2026
Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance studyBuze Chala, Lucien Platon, Yssimini Nadège Guillène Tibiri, et al.
The Lancet. Infectious Diseases|August 21, 2026
Severe health-care-associated infections and antimicrobial resistance in an Asian Surveillance Network (ACORN-HAI): a multicentre, prospective cohort studyYin Mo, Xinxin Hao, Ying Ding, et al.
The Lancet. Infectious Diseases|August 14, 2026
Guiding principles for pragmatic randomised trials of tuberculosis treatmentsPatrick P J Phillips, Samuel G Schumacher, Cara Cassino, et al.
The Lancet. Infectious Diseases|August 19, 2026
Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled studyFrederic Sawe, Lucy Koech, Souhir Neffati, et al.
The Lancet. Infectious Diseases|August 31, 2026
Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trialLindsey R Baden, Nirav S Shah, Sean T H Liu, et al.
Pageof 270